抗精神病药对伴精神病性特征的重性抑郁障碍患者脑结构的影响:随机安慰剂对照试验的神经影像学发现
该研究为一项双盲随机安慰剂对照试验的预设二次分析,纳入伴精神病性特征的重性抑郁障碍患者,先接受奥氮平联合舍曲林治疗12至20周,随后随机继续原方案或换为安慰剂联合舍曲林治疗36周。结果显示,与安慰剂相比,奥氮平暴露与皮层厚度显著下降相关,但复发本身也与皮层厚度下降相关。
要点
- 奥氮平暴露与伴精神病性特征抑郁患者皮层厚度下降相关
- 复发患者也出现皮层厚度下降,支持急性期抗精神病药治疗
- 该信息对存在替代方案时的精神科处方有参考价值
核心结论
- 在伴精神病性特征的重性抑郁障碍患者中,抗精神病药奥氮平暴露与脑结构改变相关,表现为皮层厚度下降。
- 复发本身也与皮层厚度下降相关,支持在疾病活跃期使用抗精神病药治疗。
研究设计与样本
- 研究为多中心、双盲、随机、安慰剂对照试验的预设二次分析,为期36周,共5个学术中心参与。
- 参与者为18至85岁伴精神病性特征的重性抑郁障碍患者,先接受奥氮平联合舍曲林治疗12至20周,达到精神病性症状缓解及抑郁缓解或接近缓解后随机分组。
- 随机后继续原方案或换为安慰剂联合舍曲林治疗36周,同意者分别在随机时和36周末或复发时完成脑磁共振成像扫描。
主要发现
- 皮层厚度存在显著的治疗组与时间交互作用(左侧t=3.3,P=.001;右侧t=3.6,P<.001),表面积无显著交互作用。
- 白质骨架平均弥散率存在显著治疗组与时间交互作用(t=-2.6,P=.01),各向异性分数无显著交互作用。
- 在持续缓解者中,与安慰剂相比,奥氮平暴露与左半球皮层厚度显著下降相关(β[SE]=0.04[0.009];t34.4=4.7;P<.001),右半球亦显著下降(β[SE]=0.03[0.009];t35.1=3.6;P<.001)。
- 事后分析显示,接受安慰剂后复发者与持续缓解者相比,皮层厚度出现下降。
关键数值与推荐
- 主要结局为灰质皮层厚度,次要结局为白质微结构完整性。
- 持续缓解者中奥氮平组较安慰剂组皮层厚度下降的左侧β[SE]=0.04[0.009],t34.4=4.7,P<.001;右侧β[SE]=0.03[0.009],t35.1=3.6,P<.001。
- 白质骨架平均弥散率治疗组与时间交互作用t=-2.6,P=.01。
临床怎么用
- 在存在替代方案的精神疾病中,处方抗精神病药时需权衡其对脑结构的潜在影响。
- 疾病活跃期使用抗精神病药治疗获得缓解,可能避免复发相关的脑结构改变。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prescriptions for antipsychotic medications continue to increase across many brain disorders, including off-label use in children and elderly individuals. Concerning animal and uncontrolled human data suggest antipsychotics are associated with change in brain structure, but to our knowledge, there are no controlled human studies that have yet addressed this question. OBJECTIVE: To assess the effects of antipsychotics on brain structure in humans. DESIGN, SETTING, AND PARTICIPANTS: Prespecified secondary analysis of a double-blind, randomized, placebo-controlled trial over a 36-week period at 5 academic centers. All participants, aged 18 to 85 years, were recruited from the multicenter Study of the Pharmacotherapy of Psychotic Depression II (STOP-PD II). All participants had major depressive disorder with psychotic features (psychotic depression) and were prescribed olanzapine and sertraline for a period of 12 to 20 weeks, which included 8 weeks of remission of psychosis and remission/near remission of depression. Participants were then were randomized to continue receiving this regimen or to be switched to placebo and sertraline for a subsequent 36-week period. Data were analyzed between October 2018 and February 2019. INTERVENTIONS: Those who consented to the imaging study completed a magnetic resonance imaging (MRI) scan at the time of randomization and a second MRI scan at the end of the 36-week period or at time of relapse. MAIN OUTCOMES AND MEASURES: The primary outcome measure was cortical thickness in gray matter and the secondary outcome measure was microstructural integrity of white matter. RESULTS: Eighty-eight participants (age range, 18-85 years) completed a baseline scan; 75 completed a follow-up scan, of which 72 (32 men and 40 women) were useable for final analyses. There was a significant treatment-group by time interaction in cortical thickness (left, t = 3.3; P = .001; right, t = 3.6; P < .001) but not surface area. No significant interaction was found for fractional anisotropy, but one for mean diffusivity of the white matter skeleton was present (t = -2.6, P = .01). When the analysis was restricted to those who sustained remission, exposure to olanzapine compared with placebo was associated with significant decreases in cortical thickness in the left hemisphere (β [SE], 0.04 [0.009]; t34.4 = 4.7; P <.001), and the right hemisphere (β [SE], 0.03 [0.009]; t35.1 = 3.6; P <.001). Post hoc analyses showed that those who relapsed receiving placebo experienced decreases in cortical thickness compared with those who sustained remission. CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, antipsychotic medication was shown to change brain structure. This information is important for prescribing in psychiatric conditions where alternatives are present. However, adverse effects of relapse on brain structure support antipsychotic treatment during active illness. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01427608.
引用
- Voineskos AN, Mulsant BH, Dickie EW, et al. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial. JAMA Psychiatry. 2020. PMID: 32101271. doi:10.1001/jamapsychiatry.2020.0036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。